overview

Asia’s pharma markets are extremely complex with each country governed by very different healthcare policies, reimbursement schemes, unique pricing, with large risks involved in entering the market, particularly with high priced, specialty drugs/therapeutics. Once way is to overcome this is to out-license, which cuts risks but can also decrease profits. There is also no guarantee that this will lead to success.

2nd Annual Pharma Market Access Asia 2018 brings pharma and industry together to navigate the complex environments and lessons learnt from successfully and profitable market entries for orphan drugs, high priced therapeutics, generics, biosimilars and more.

“Excellent event! Looking at multiple perspective from patients, policy maker, prescriber, provider, and payers. Well done to the producer and organizing team!”
Sebastien Boisseau, Market Access Director, Mundipharma

Snapshot of 2018 Attendee List:

View »

Conference Highlights

• Country Case Studies – On market access by Pharma companies
• Growth Markets and Strategy Spotlight for Biosimilars, Generics, Orphan drugs, etc
• Pricing and Reimbursement – Strategies for improving market access
• Leveraging HEOR and RWE – In support of Market Access
• Out Licensing and Partnerships – For successful collaboration models

Choose your language

• 日本語 »
• 한국어 »
• 简体中文 »
• 繁体中文 »

Part of

Pharmacon Asia >>

Co-Located Events

Accelerating Clinical Trials in Asia >>
Pharma Regulatory Affairs Asia >>
Pharma Market Access and Pricing Summit Asia >>
Digital Pharma Summit >>